PP
VNDA icon

PDT Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

PDT Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-39,933
Closed -$263K – 687
2023
Q2 		$263K Hold
39,933
– – 0.04% 474
2023
Q1 		$271K Buy
+39,933
New +$281K 0.04% 474
2022
Q4 		– Sell
-20,065
Closed -$198K – 907
2022
Q3 		$198K Sell
20,065
-20,742
-51% -$219K 0.03% 723
2022
Q2 		$445K Buy
40,807
+18,027
+79% +$187K 0.04% 631
2022
Q1 		$258K Buy
22,780
+10,322
+83% +$136K 0.02% 764
2021
Q4 		$195K Buy
+12,458
New +$217K 0.01% 768
2021
Q3 		– Sell
-57,998
Closed -$1.25M – 925
2021
Q2 		$1.25M Buy
57,998
+1,004
+2% +$18K 0.08% 334
2021
Q1 		$856K Buy
56,994
+11,033
+24% +$179K 0.06% 397
2020
Q4 		$604K Sell
45,961
-35,639
-44% -$429K 0.04% 419
2020
Q3 		$788K Sell
81,600
-15,948
-16% -$170K 0.05% 348
2020
Q2 		$1.12M Buy
97,548
+67,412
+224% +$763K 0.08% 266
2020
Q1 		$312K Buy
+30,136
New +$374K 0.02% 474
2017
Q3 		– Sell
-98,360
Closed -$1.6M – 571
2017
Q2 		$1.6M Sell
98,360
-10,500
-10% -$151K 0.06% 280
2017
Q1 		$1.52M Hold
108,860
– – 0.08% 258
2016
Q4 		$1.74M Sell
108,860
-10,800
-9% -$174K 0.11% 263
2016
Q3 		$1.99M Buy
119,660
+3,900
+3% +$52.5K 0.12% 226
2016
Q2 		$1.29M Sell
115,760
-12,400
-10% -$120K 0.1% 235
2016
Q1 		$1.07M Sell
128,160
-46,400
-27% -$381K 0.07% 303
2015
Q4 		$1.63M Sell
174,560
-105,155
-38% -$1.05M 0.22% 165
2015
Q3 		$3.15M Buy
279,715
+170,625
+156% +$2.09M 0.07% 319
2015
Q2 		$1.38M Buy
+109,090
New +$1.18M 0.04% 621

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PDT Partners's VNDA Position: Q3 2023 in Review

PDT Partners sold out of Vanda Pharmaceuticals (VNDA) in Q3 2023, closing a stake of 39,933 shares — an estimated $263K sold.

PDT Partners first reported a position in VNDA in Q2 2015 and held it in 21 quarters. The position peaked at $3.15M in Q3 2015. 179 funds tracked by Wall St. Rank hold VNDA as of Q3 2023.

  • PDT Partners reported no remaining Vanda Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • PDT Partners sold 39,933 Vanda Pharmaceuticals shares in Q3 2023, an estimated $263K.
  • PDT Partners first reported a position in Vanda Pharmaceuticals in Q2 2015 and held it in 21 quarters.
  • PDT Partners's Vanda Pharmaceuticals position peaked at $3.15M in Q3 2015.
  • 179 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2023.

Based on PDT Partners's 13F filing for Q3 2023, filed 14 Nov 2023.